HealthEquity (NASDAQ:HQY) Given Outperform Rating at Barrington Research

Barrington Research restated their outperform rating on shares of HealthEquity (NASDAQ:HQY) in a report released on Friday,Benzinga reports. They currently have a $112.00 price objective on the stock.

A number of other equities analysts have also issued reports on HQY. The Goldman Sachs Group dropped their target price on shares of HealthEquity from $107.00 to $94.00 and set a “neutral” rating on the stock in a research report on Thursday, March 27th. Wells Fargo & Company boosted their price objective on shares of HealthEquity from $110.00 to $125.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. KeyCorp reduced their target price on shares of HealthEquity from $120.00 to $110.00 and set an “overweight” rating for the company in a research note on Monday, March 24th. Finally, Raymond James upgraded HealthEquity from an “outperform” rating to a “strong-buy” rating and lowered their price target for the company from $120.00 to $115.00 in a research note on Tuesday, March 25th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $112.58.

HealthEquity Stock Performance

HQY opened at $82.20 on Friday. HealthEquity has a 12-month low of $65.01 and a 12-month high of $115.59. The firm has a market capitalization of $7.11 billion, a P/E ratio of 75.41, a price-to-earnings-growth ratio of 1.60 and a beta of 0.49. The stock’s 50 day moving average price is $97.63 and its two-hundred day moving average price is $96.30. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.51.

Insider Transactions at HealthEquity

In other HealthEquity news, Director Robert W. Selander sold 5,750 shares of the business’s stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $77.65, for a total value of $446,487.50. Following the transaction, the director now directly owns 84,969 shares in the company, valued at $6,597,842.85. The trade was a 6.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael Henry Fiore sold 8,881 shares of the company’s stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $78.26, for a total transaction of $695,027.06. Following the sale, the executive vice president now directly owns 56,655 shares in the company, valued at $4,433,820.30. This represents a 13.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,381 shares of company stock valued at $1,781,432. Corporate insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On HealthEquity

Several institutional investors have recently bought and sold shares of the business. Congress Asset Management Co. increased its stake in shares of HealthEquity by 168.0% in the first quarter. Congress Asset Management Co. now owns 68,253 shares of the company’s stock valued at $6,032,000 after buying an additional 42,785 shares in the last quarter. Radnor Capital Management LLC grew its holdings in HealthEquity by 6.2% during the 1st quarter. Radnor Capital Management LLC now owns 6,040 shares of the company’s stock worth $534,000 after acquiring an additional 350 shares during the last quarter. Chesley Taft & Associates LLC increased its position in HealthEquity by 44.7% in the 1st quarter. Chesley Taft & Associates LLC now owns 12,622 shares of the company’s stock valued at $1,115,000 after acquiring an additional 3,897 shares in the last quarter. Portside Wealth Group LLC bought a new position in shares of HealthEquity in the first quarter worth about $225,000. Finally, Hennion & Walsh Asset Management Inc. raised its stake in shares of HealthEquity by 40.0% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 3,137 shares of the company’s stock worth $277,000 after acquiring an additional 897 shares during the last quarter. Institutional investors own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.